In a study published Oct. 14 in JAMA, researchers examined 166 clinical trials tied to applications for new drugs and biologics submitted between 2010 and 2019. During that time, people 75 and older were underrepresented for Type 2 diabetes and non-small cell lung cancer. And trials for nonvalvular atrial fibrillation stroke prevention, insomnia, heart failure and osteoporosis failed to include enough participants who were 80 and older.
This inconsistency in age group representation for new drug applications could hide the overall efficacy of these drugs because “older adults may represent significant proportions of the treatment population,” the researchers concluded.
Trial enrollment efforts for older populations may be hindered by polypharmacy, multimorbidity and organ dysfunction, but the study’s authors said closing the gap requires regulatory action.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
